215 related articles for article (PubMed ID: 19956806)
1. Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Sonpavde G; Hutson TE; Sternberg CN
Drugs Today (Barc); 2009 Sep; 45(9):651-61. PubMed ID: 19956806
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
McCormack PL
Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib: in advanced renal cell carcinoma.
Sanford M; Keating GM
BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
11. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Sonpavde G; Hutson TE
Curr Oncol Rep; 2007 Mar; 9(2):115-9. PubMed ID: 17288876
[TBL] [Abstract][Full Text] [Related]
16. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
[TBL] [Abstract][Full Text] [Related]
17. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Biró K; Küronya Z
Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib.
Bukowski RM; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
[TBL] [Abstract][Full Text] [Related]
20. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
